Lacidipine metabolism in rat and dog: identification and synthesis of main metabolites.

1. The main metabolites of lacidipine were isolated from bile and plasma of rats and dogs following an oral dose of the 14C-labelled drug (10 mg/kg for rats: 2 and 1 mg/kg for dogs). They were identified by comparison of chromatographic and spectral data with authentic reference compounds synthesized ad hoc. 2. Five metabolites (I-V) were isolated and identified in dog bile by gradient h.p.l.c. with u.v. detection and h.p.l.c.-thermospray mass spectrometry. In all metabolites the heterocyclic ring has been oxidized to pyridine. Further biotransformation reactions involved hydroxylation of the methyl substituents and hydrolysis of the ethyl and t-butyl ester groups to produce carboxylic acids and a lactone. Some of these metabolites also occurred as glucuronide conjugates. 3. A metabolite retaining the intact dihydropyridine ring, the des-ethyl analogue of lacidipine (VI), was isolated from rat plasma where it accounted for 60% of the total circulating radioactivity up to 24 h after administration. To characterize this metabolite, h.p.l.c. with photodiode array u.v. detection also was employed. This compound was detected in dog plasma, but there was no evidence of its presence in dog bile samples. 4. Profiles of circulating metabolites were qualitatively similar in rats and dogs. Identified metabolites accounted for the large majority of total radioactivity in all the analysed samples.

[1]  G. Gaviraghi,et al.  Lacidipine: A Calcium Antagonist with Potent and Long‐Lasting Antihypertensive Effects in Animal Studies , 1990, Journal of cardiovascular pharmacology.

[2]  J. Ayrton,et al.  Absorption, distribution and excretion of lacidipine, a dihydropyridine calcium antagonist, in rat and dog. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  Y. Iwasawa,et al.  Metabolism of a new dihydropyridine calcium antagonist in rats and dogs. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  H. Ahr,et al.  Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man. , 1988, Arzneimittel-Forschung.

[5]  A. Beresford,et al.  Metabolism of amlodipine in the rat and the dog: a species difference. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  S. Terashita,et al.  Metabolism of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  Parinov Vj,et al.  Pharmacokinetics and metabolism of ryodipine in rats. , 1985 .

[8]  K. Hoffmann,et al.  Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  W. Karl,et al.  Nitrendipine: identification and synthesis of main metabolites. , 1984, Arzneimittel-Forschung.

[10]  F. Bossert,et al.  Nimodipine: synthesis and metabolic pathway. , 1983, Arzneimittel-Forschung.

[11]  S. Higuchi,et al.  Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. , 1977, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  T. Flanagan,et al.  Metabolism of the antihypertensive agent 1,4-dihydro-2,6-dimethyl-4-(2-trifluoromethylphenyl)-3,5-pyridinedicarboxylic acid diethyl ester. , 1973, Journal of pharmaceutical sciences.

[13]  C. Wünsche,et al.  [Structural analysis of the renal excretion products of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester]. , 1972, Arzneimittel-Forschung.